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Abstract
Sepsis is a life threatening disease that is associated with high mortality. Existing treatments have 
failed to improve survivability in septic patients. The purpose of this present study is to evaluate 
whether cerium oxide nanoparticles (CeO2NPs) can prevent lipopolysaccharide (LPS) induced 
severe sepsis mortality by preventing hepatic dysfunction in male Sprague Dawley rats. 
Administration of a single dose (0.5 mg/kg) of CeO2NPs intravenously to septic rats significantly 
improved survival rates and functioned to restore body temperature, respiratory rate and blood 
pressure towards baseline. Treatment-induced increases in animal survivability were associated 
with decreased hepatic damage along with reductions in serum cytokines/chemokines, and 
diminished inflammatory related signaling. Kupffer cells and macrophage cells exposed to 
CeO2NPs exhibited decreases in LPS-induced cytokine release (TNF-α, IL-1β, IL-6, HMGB1) 
which were associated with diminished cellular ROS, reduced levels of nitric oxide synthase 
(iNOS), cyclooxygenase 2 (COX-2), and decreased nuclear factor-kappa light chain enhancer of 
activated B cells (NF-kB) transcriptional activity. The findings of this study indicate that 
CeO2NPs may be useful as a therapeutic agent for sepsis.
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1. Introduction
Severe sepsis is associated with a systemic inflammatory response syndrome (SIRS) that is 
characterized by widespread elevations in reactive oxygen species (ROS) and increased 
levels of circulating tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6). The 
development of SIRS is a primary cause of multiple-organ dysfunction syndrome (MODS) 
and death in septic patients [1,2]. Although the SIRS response can be elicited by 
mycobacteria, parasites, fungus, and viruses it is thought that exposure to gram negative 
bacteria and lipopolysaccharide (LPS) is the predominant cause [3,4]. Amongst the different 
organ systems affected by sepsis, the liver appears to be amongst the first organs affected as 
the liver macrophages (Kupffer cells) have been shown to play a key role in the removal of 
xenobiotics from the blood [5]. It is well documented that LPS stimulation of the Kupffer 
cells results in the release various cytokines/chemokines including TNF-α, IL-6, HMGB1, 
and nitric oxide (NO) [6], which have been shown to induce SIRS development [7,8].
The factors regulating the release of cytokines from macrophages are not fully understood 
although it has been hypothesized that this process is regulated, at least in part, by increases 
in cellular ROS which has led some to hypothesize that the use of antioxidants may be 
valuable for the treatment of sepsis [9–11]. Although promising in animals, the vast majority 
of interventional studies examining the effects of antioxidant therapies have been largely 
ineffective in clinical trials [12]. The reasons for these failures are currently unknown and 
likely complex in nature but may be related to the fact that the treatment of sepsis is 
oftentimes hindered by the sepsis-associated circulatory abnormalities, poor bio-distribution, 
and individual differences in the septic presentation. In addition, the use of traditional 
pharmacological approaches can be limited by the need for multiple daily dosing since each 
anti oxidant molecule is typically capable of scavenging only one free radical [13]. In an 
effort to overcome these limitations, we sought to develop a treatment that would not only 
target the liver Kupffer cells which are responsible for initiating SIRS development, but one 
that was also capable of exhibiting continued activity over time.
Ceria is a rare earth element of the lanthanide series that is used in automobile catalytic 
converters to convert carbon monoxide to carbon dioxide [14]. In its oxide form, ceria can 
transition between Ce3+ and Ce4+ oxidative states which can allow for auto regenerative 
redox cycling and free radical scavenging [13]. Although the use of CeO2 in nanoparticle 
form for biomedical applications awaits further development, previous reports have 
indicated that these particles possess antioxidative activity [14] and that they tend to 
accumulate in the Kuppfer cells when injected into the systemic circulation of the laboratory 
rat [15]. On the basis of these data, we hypothesized that the systemic administration of 
CeO2 nanoparticles would be associated with diminished Kupffer cell cytokine/chemokine 
release and decreased SIRS development which would result in improved animal survival 
following sepsis insult.
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2. Material and methods
2.1. Cerium oxide nanoparticle preparation and characterization
The CeO2 nanoparticles were purchased from Sigma–Aldrich (USA) and characterized as 
outlined. Stock suspensions (3.5 mg/ml) were prepared in ddH2o by sonication (600 W for 2 
min) using a Vibra Cell Sonicator (Sonics & Materials, Inc.) at room temperature and 
characterized. Dynamic light scattering (DLS) was performed to estimate the mean size of 
CeO2 NPs in suspension using LB-550 DLS particle size analyzer (Horiba Scientific, 
Edison, NJ). Naked particle size of the CeO2 NPs was characterized by transmission 
electron microscopy (TEM) using JEOL JEM 1200Ex. X-ray diffraction (XRD) was 
performed using a Scintag XDS 2000 powder diffractometer. Scanning transmission 
electron microscopy (STEM) images were acquired using a JEM-ARM200CF (JEOL, 
Japan) operated at 200 keV. The oxidative state of cerium was analyzed by X-ray 
photoelectron spectroscopy (XPS) using a PHI ESCA 5400 spectrophotometer.
2.2. Animal preparation and experimental design
Animals were prepared for experiments as detailed in the Selvaraj et al. [16] and were 
randomly assigned to one of four groups. The control group (n = 6) received 1.5 ml of 
endotoxin free water by i.p. while the CeO2 nanoparticle treated group (n = 6) received 1.5 
ml of endotoxin free water by i.p. and CeO2 nanoparticles (0.5 mg/kg) in 200 μl of sterile 
distilled water via the tail vein. The LPS treated group (n = 12) received LPS (055-B5; 40 
mg/kg, Sigma, St. Louis, MO) in 1.5 ml of sterile water by i.p. and 200 μl of sterile distilled 
water via the tail vein while the LPS + CeO2 NPs treatment group received LPS (40 mg/kg) 
in 1.5 ml of sterile water by i.p. and CeO2 nanoparticles (0.5 mg/kg) in 200 μl of sterile 
distilled water via the tail vein. The animal survival rate was assessed for a period of 7 days. 
LPS-induced sepsis symptoms were quantitated by monitoring animal behavior, body 
temperature and respiratory rate using a Mouse Ox Plus from Star Scientific Corp 
(Massachusetts, USA), while heart rate and blood pressure were evaluated using a CODA 
blood pressure system from Kent Scientific (Connecticut, USA).
2.3. Sample collection, estimation of blood cell number and quantification of serum 
cytokines
In an additional set of experiments, blood and livers were collected at 6 or 24 h after study 
initiation. Differential blood cells were estimated in whole blood using an Abaxis VetScan 
HM2 hematology analyzer (Abaxis, Union city, CA). Serum TNF-α levels were analyzed by 
enzyme-linked immunosorbent assay (ELISA) (BD Bioscience, Franklin Lakes, NJ). Serum 
samples from each of the different groups (n = 6/group) were pooled and sent to Myriad 
RBM (Austin, TX) for the analysis of cytokines, chemokines and markers of inflammation 
using rodent MAP® V. 3.0 as detailed elsewhere [17,18]. Nitrite in the serum was assayed 
using the Griess reaction using a kit from Cayman Chemical Company (Ann Arbor, 
Michigan, USA).
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2.4. Estimation of CeO2 nanoparticle content in the liver and analysis of liver damage
Liver ceria content was estimated by induction coupled plasma-mass spectrometry (ICP-
MS) as described elsewhere [18]. In other experiments, portions of each liver were formalin 
fixed, sectioned, and stained with hematoxylin and eosin (H&E) for histopathological 
examination. Microscopic images were captured using an EVOS XL Core microscope 
(Fisher Scientific, Pittsburgh, PA, USA). Liver damage markers in the serum were estimated 
using an Abaxis VetScan analyzer (Abaxis, UnionCity, CA) and Myriad RBM (Austin, TX).
2.5. Immunoblotting and TUNEL staining
Proteins samples were prepared from the liver for immunoblotting as detailed in Selvaraj et 
al. [16]. Liver cell apoptosis was assessed using a transferase-mediated dUTP nick-end 
labeling (TUNEL) kit (Roche Applied Science, Indianapolis, IN) as described in Selvaraj et 
al. [16].
2.6. Kupffer cell isolation and assays
Kupffer cells were isolated from rat liver and purified by differential centrifugation using a 
Percoll gradient as described previously [19]. The purity of the KCs was determined by ED1 
and ED2 staining (immunofluorescence) as described [7]. KCs were cultured and treated 
with LPS in the presence and absence of CeO2 nanoparticles for 24 h and TNF-α release 
was measured by ELISA. Reactive oxygen species (ROS) levels were determined using the 
OxiSelect™ kit from Cell Bio Labs (San Diego, CA), as outlined by the manufacturer.
2.7. Macrophage uptake of CeO2 nanoparticles and effect against LPS challenge
The cytotoxic and protective effect of CeO2 nanoparticles against LPS challenge was 
determined by the MTT assay as described in Selvaraj et al. [16]. CeO2 nanoparticle uptake 
by the macrophage cells was estimated by inductively coupled plasma-mass spectrometry 
(ICP-MS) at Elementary Analysis Inc (Lexington, Kentucky, USA) as described previously 
[20].
ROS levels were determined using the OxiSelect™ kit from Cell Bio Labs (San Diego, CA) 
while mitochondrial membrane damage was estimated by Δψm using the JC 1 dye (Cell 
Technology, Mountain View, CA) as described elsewhere [21]. Nitrite production was 
assayed using the Griess reaction kit from Cayman Chemical Company (Ann Arbor, 
Michigan, USA) as described by the manufacturer. The concentration of TNF-α, IL-6, IL-1β 
and HMGB1 in the media was measured by ELISA reagent kits as described in Selvaraj et 
al. [16].
2.8. Electromobility shift and luciferase reporter assays
The electromobility shift (EMSA) assay was performed using a commercially available kit 
(Pierce, Rockford, IL, USA) as described in Selvaraj et al. [16]. Luciferase reporter assays 
were performed using a NF-kB reporter construct from Promega (Madison, WI, USA) as 
detailed in Selvaraj et al. [16].
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Data are presented as mean ± standard error of the mean (SEM). Dependent variables were 
analyzed by one way ANOVA by Holm-Sidak test using SigmaStat (Aspire Software 
International, Auburn VA) and post-hoc testing where appropriate. A P < 0.05 was 
considered as significant.
3. Results
3.1. Characterization of CeO2 nanoparticle
SEM and TEM analysis determined the size of individual nano-particles to be between 200 
and 400 nm (Fig. 1A(i, ii)). The mean hydrodynamic diameter of CeO2 nanoparticles as 
estimated by dynamic light scattering was 53.36 ± 7.04 nm (Fig. 1B(i)). XRD spectral 
analysis confirmed the purity of CeO2 nanoparticles preparation and demonstrated well 
defined peaks 2Ɵ = 28.5, 33.1, 47.5, 56.2, 59.0 and 69.2. No other peaks related to 
impurities were detected (Fig. 1B(ii)). XSP spectral analysis indicated a higher 
concentration of Ce4+ than Ce3+ in the CeO2 nanoparticles (Fig. 1C(i)).
3.2. Effect of CeO2 nanoparticle treatment on animal mortality and physiological function
Nanoparticle treatment decreased LPS-induced mortality from 70 % to 10 % (Fig. 1C(ii), P 
< 0.05). Increases in animal survivability were associated with improvements in animal 
behavior (Selvaraj et al. Table 1 [16]), core body temperature (Fig. 1D(i), P < 0.05), 
decreased respiratory rate (Fig. 1D(ii)), and increases in blood pressure (Fig. 1E). Sepsis 
decreased the percentage of lymphocytes and increased the percentage of granulocytes at 6 
and 24 h. Nanoparticle treatment reversed these changes at the 6 h time point (Selvaraj et al. 
Table 2 P < 0.05 [16]).
3.3. Nanoparticle treatment decrease sepsis related systemic inflammation
Compared to controls, LPS-induced sepsis was associated with increased serum cytokines, 
chemokines and acute phase proteins including tumor necrosis factor alpha (TNF-α), 
interleukin-1 beta (IL-1β), interleukin-1 alpha (IL-1α) at 6 h (P < 0.05). Nanoparticle 
treatment decreased serum TNF-α, IL-1β levels at 6 h and IL-1α at both 6 and 24 h (Fig. 
2A(i,ii) and B(i), P < 0.05). Compared to controls, LPS-induced sepsis appeared to increase 
the amount of macrophage derived chemokine (MDC), macrophage inflammatory protein-1 
beta (MIP-1 β), macrophage inflammatory protein-2 (MIP-2), macrophage inflammatory 
protein-3 beta (MIP-3 β), macrophage inflammatory protein-1 alpha (MIP-1 α), monocyte 
chemotactic protein-1 (MCP-1), monocyte chemotactic protein-3 (MCP-3), granulocyte 
chemotactic protein 2 (GCP-2), and growth regulated alpha protein (KC/GROα)at 6 and 24 
h (Fig. 2B(ii) to F(ii)). Nanoparticle administration decreased the levels of MIP-2, MIP-3β, 
MCP-1, MCP-3, GCP-2 and KC/GROα at both 6 and 24 h (P < 0.05) (Fig. 2C(ii) to F(ii)). 
The expression of several other acute phase and inflammatory proteins including stem cell 
factor, myoglobin, CD-40 ligand, fibrinogen, growth hormone, heptaglobin, leptin, and 
interferon gamma induced protein 10 (IF-10) were also altered with sepsis and with 
treatment (Selvaraj et al. Table 3 [16]).
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3.4. Nanoparticle treatment increase liver ceria content and protects the liver against 
sepsis induced damage
Compared to untreated animals, liver ceria content was increased in the nanoparticle injected 
animals (Fig. 3A(ii)). Sepsis associated decreases in liver weight were attenuated with 
nanoparticle treatment (Fig. 3A(iii), P < 0.05). Histological analyses of the livers obtained 
from control animals were unremarkable. Sepsis was associated with changes in cell 
swelling, inflammation, necrosis, sinusoidal dilatation and the infiltration of cells in the 
portal area (Fig. 3B) which appeared to be diminished with nanoparticle treatment. 
Consistent with these changes in liver histology, sepsis was found to increase serum 
bilirubin (TBIL) at 24 h while serum alanine aminotransferase (ALT), glutathione S-
transferase Mu (GST-Mu), and glutathione S-transferase alpha (GST-α) levels were elevated 
at 6 and 24 h. Nanoparticle treatment decreased serum bilirubin, ALT, GST-Mu, and GST-α 
(Fig. 3C (i to iii) and D(i), P < 0.05).
3.5. Nanoparticle treatment decrease sepsis related increase in MyD88, MAPK activation, 
iNOS and HMGB1
Compared to that seen in the control animals, sepsis increased the expression of MyD 88, 
and the phosphorylation of p38-MAPK and p44/42-MAPK which were decreased with 
nanoparticle treatment (Fig. 3D(ii) and E(i, ii), P < 0.05). Sepsis increased serum nitrite 
levels at 6 and 24 h. Nanoparticle treatment decreased LPS-induced nitrite production (Fig. 
3A (i)) along with LPS associated increases in liver iNOS and HMBG-1 content (Fig. 4A(i, 
ii), P < 0.05).
3.6. Nanoparticle treatment decrease hepatic apoptosis during sepsis
To investigate the possibility that changes in liver structure were associated with cellular 
apoptosis we determined the number of nuclei staining positively for DNA fragmentation by 
TUNEL staining. As expected, we found that sepsis increased and that nanoparticle 
treatment decreased the number of TUNEL positive nuclei (Fig. 4A (iii), Fig. 4B, P < 0.05). 
These decreases in cellular apoptosis with treatment were associated with decreased 
caspase-3 cleavage (19 and 17-kDa fragments) (Fig. 4C (i), P < 0.05) and a decrease in the 
Bax/Bcl-2 ratio (Fig. 4C (ii), P < 0.05).
3.7. Nanoparticle treatment decrease LPS-induced increase in macrophage ROS level and 
cytokine release
Based on the fact that many of the cytokines/chemokines and other inflammatory regulators 
observed during SIRS are likely derived from the liver Kupffer cells [22] and from our 
serum profiling data (Fig. 2 and Selvaraj et al. Table 3 [16]) we next examined the effect of 
LPS challenge on Kupffer cell function in the absence and presence of CeO2 nanoparticles. 
Compared to control cells, LPS challenge was associated with alterations in cellular 
morphology, increased TNF-α production, and elevations in cellular ROS levels which 
appeared to be diminished with nanoparticle treatment (Fig. 4D, C(iii) and E).
Because of the difficulties associated with the continued propagation of Kuppfer cells in 
culture we next examined the effects of nanoparticle treatment in depth using cultured 
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RAW264.7 macrophages. Dose response toxicity experiments using the MTT assay 
suggested that nanoparticle dosages greater than 1 μg/ml appeared to be cytotoxic (Selvaraj 
et al. [16] Fig. 1, P < 0.05). Consistent with our in vivo data, LPS-induced increases in cell 
death were diminished with nanoparticle treatment (25, 50,100 or 1000 ng/ml) (Fig. 5A (i), 
P < 0.05). To test if the improvements in cell survival were associated with the ability of the 
nanoparticles to bind to/sequester LPS or if exposure to the nanoparticles was able to 
neutralize LPS functionality, varying doses of CeO2 nanoparticles (0,1, 5,10, 25, 50,100, or 
1000 ng/ml) were added to growth media containing LPS (2 μg/ml) and allowed to interact. 
After centrifugation to remove any suspended nanoparticles, the MTT assay was performed 
using the clarified media. Consistent with the possibility that the nanoparticles do not act to 
impair LPS functionality, we did not observe any differences in the amount of cell death 
caused between incubation of the cells with “native” and nanoparticle “exposed” LPS (Fig. 
5 A (ii)). The uptake of CeO2 nanoparticles by the RAW264.7 cells in the presence or 
absence of LPS was confirmed using ICP-MS (Fig. 5)B(i).
To investigate whether changes in cell survival were associated with alterations in cellular 
ROS, RAW264.7 cells were stained with DCFH-DA and JC-1 dyes to determine the effects 
of nanoparticle treatment on cellular superoxide levels and mitochondrial membrane 
potential (Δψm) levels, respectively [23,24]. As might be expected given the potential ROS 
scavenging ability of CeO2 nanoparticles [13,14], nanoparticle treatment was found to 
decrease LPS-induced increases in cellular ROS and mitochondrial membrane potential 
(Fig. 6A (i,ii), P < 0.05).
In addition to changes in cellular ROS, nanoparticle treatment also decreased the production 
of TNF-α, IL-6, IL-1β, and HMGB1 following LPS challenge (Fig. 5B (ii) to D(i), P<0.05). 
Similarly, nanoparticle treatment also decreased nitrite production, along with the 
upregulation of iNOS and COX-2 protein following LPS challenge (Fig. 5D(ii) to E(i,ii), (P 
< 0.05)).
3.8. Nanoparticle treatment decrease NF-kB/p65 transcriptional activity
LPS-induced decreases in IkB-α protein were abrogated following nanoparticle treatment 
(Fig. 6B (i), P < 0.05). Consistent with these data, nanoparticle treatment also decreased 
LPS-induced translocation of NF-kB/p65 to the nucleus (Fig. 6B (ii), C(i)), NF-kB/p65 
binding to DNA (Figure C(ii), D(i)), and LPS-associated increases in NF-kB transcriptional 
activity (Fig. 6D (ii), P < 0.05).
4. Discussion
Despite decades of intensive investigation and significant advances in medical technology, 
the overall mortality rate in severe sepsis patients remains unacceptably high. The aim of 
this study was to evaluate whether CeO2 nanoparticles are protective against LPS-induced 
sepsis in the Sprague Dawley rat. The primary finding of this study was that a single 
injection of CeO2 nanoparticles, in the absence of antibiotic treatment, fluid resuscitation, or 
other pharmacological intervention, was able to increase animal survivability 200% 
following a severe septic insult (Fig. 1C (ii)).
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Consistent with previous studies we found that severe sepsis was associated with changes in 
body temperature, respiratory rate, and blood pressure and blood cell counts [2,25,26]. 
Nanoparticle treatment attenuated sepsis-induced changes in these variables (Fig. 1D (i,ii), 
and E)). Given that serum cytokine/chemokine levels are highly correlated with patient 
survival [27] we next sought to determine if the nanoparticle treatment functioned to 
diminish SIRS development. As expected, we found that sepsis was associated with the 
significant upregulation of a number of different cytokines, chemokine, acute phase 
proteins, and other inflammatory mediators and importantly, that the nanoparticle treatment 
appeared to significantly blunt many of these sepsis-induced changes (Fig. 2 and Selvaraj et 
al. Table 3 [16]). These latter data are in agreement with the previous work of Kyosseva and 
colleagues who demonstrated that a single injection of nanoceria in the neurodegeneration 
prone Vldlr–/– mouse was able to attenuate the expression of several proinflammatory 
cytokines and proangiogenic growth factors [28].
To explore the mechanistic basis of this finding, we next determined where the injected 
CeO2 nanoparticles may accumulate. Similar to previous work [29], ICP-MS analysis 
demonstrated significantly higher amounts of ceria in the livers of the treated animals 
compared to that observed in the untreated animals (Fig. 3A (ii)). To examine if the CeO2 
nanoparticles were able to protect the liver injury against a septic insult we next examined if 
treatment was associated with improvement in liver structure and function. We observed that 
sepsis was associated with alterations in liver morphology (Fig. 3B) and evidence of 
diminished function as suggested by increased serum bilirubin levels (Fig. 3C (i)). In 
addition, we found that the LPS treated animals exhibited increased serum levels of the liver 
damage molecules alanine aminotransferase (ALT), glutathione S-transferase Mu (GST 
Mu), glutathione S-transferase alpha (GST-α), (Fig. 3C (ii, iii) and D(i)). Importantly, each 
of these measures were decreased significantly with nanoparticle treatment (Fig. 3C (i-iii) 
and D(i)). Supporting these data, we also found that the nanoparticle treatment was 
associated with diminished hepatic MyD88 levels, p-p38 MAPK phosphorylation, p-
ERK1/2, iNOS, and HMGB-1 suggesting that nanoparticle treatment was also associated 
with decreased liver inflammation (Fig. 3D (ii), E(i,ii) and Fig. 4 A(i,ii)). These data are 
consistent with the previous work of Cai et al. [30], and Kyosseva and co-workers [28] who 
also demonstrated that the administration of nanoceria was associated with decreased 
evidence of cellular inflammation and the attenuation of MAPK phosphorylation. To extend 
these findings we next examined if the nanoparticle treatment was also able to protect the 
liver from sepsis-induced apoptosis. As expected, we found that the nanoparticle treatment 
was associated with a diminished number of TUNEL positive hepatic nuclei, decreased 
caspase-3 cleavage, and a reduction in the Bax/Bcl-2 ratio (Fig. 4A (iii) 4B, and C (i-ii)).
Given that many of cytokines and chemokines (e.g. TNF-α, IL-6, MDC, MIP-1β, MIP-2, 
MIP-3β, MCP-3, KC/GROα) that we found to be elevated with sepsis and decreased with 
treatment are thought to be derived from the liver Kuppfer cells (macrophages) [5,31], we 
next examined the function of these particles in isolated Kupffer cells. We found that 
nanoparticle treatment was associated with decreased TNF-α release and cellular ROS levels 
after LPS challenge (Fig. 4C (iii) and E). Using cultured RAW264.7 macrophages which we 
could easily propagate, we repeated this experimental approach and found that the 
nanoparticle treatment decreased LPS-induced increases in the secretion of TNF-α, IL-6, 
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IL-1β and HMGB1 (Fig. 5B (ii) to D (i)). In addition to elevations in cytokine concentration, 
it has also been suggested that the large amount of nitric oxide (NO) produced during sepsis 
may play an important role in sepsis-induced mortality which has led some to postulate that 
decreasing NO levels may be beneficial [32,33]. Our in vivo and in vitro data show a 
significant decrease in the NO production in serum as well as cultured macrophages 
following nanoparticle treatment (Fig. 3A (i) and Fig. 5D (ii)). To confirm this finding, we 
next examined how CeO2 nanoparticle affected the expression of inducible nitric oxide 
synthase (iNOS) which is the enzyme thought to be responsible for much of the NO 
produced during the septic insult. Paralleling our findings of decreased serum nitrite (Fig. 
3A (i)) and diminished iNOS levels (Fig. 4A (i)) in the livers of the nanoparticle treated 
animals, we found that the nanoparticles also diminished LPS-induced expression of iNOS 
in cultured macro-phages (Fig. 5E (i)).
The mechanism(s) regulating cytokine and NO production in macrophages following LPS 
stimulation are not yet fully understood, however recent data has suggested that elevations 
in intracellular ROS levels may play an important role [34]. To examine this possibility, we 
next determined how nanoparticle treatment might affect cellular ROS and mitochondrial 
membrane potential levels by DCFH-DA and JC-1 staining. Consistent with previous 
reports using macrophages [35–37], we found that CeO2 nanoparticle treatment tended to 
decrease the induction of cellular ROS in RAW macro-phage cells and mitochondrial 
membrane potential damage following LPS challenge (Fig. 6A (i, ii)).
It is thought that NF-kB and mitogen activated protein kinases (MAPK) are key regulators 
of inflammatory gene expression [38]. Although the factors regulating NF-kB transcriptional 
activity are not fully understood, it is well known that nuclear localization of the redox 
sensitive NF-kB transcription factor is controlled by the phosphorylation and subsequent 
degradation of IkB-α [35]. It has been reported that LPS challenge (2 μg/ml) can be used to 
induce the degradation of IkB-α and nuclear localization of NF-kB/p65 in cultured 
RAW264.7 macrophages [39,40]. Consistent with our previous data, we found that 
nanoparticle treatment functioned to attenuate LPS-induced IkB-α degradation and NF-
kB/p65 trans-location from the cytoplasm to the nucleus (Fig. 6B (i,ii) and C(i)). 
Importantly, we also noted that these decreases in NF-kB trans-location were also associated 
with diminished NF-kB binding to DNA (Fig. 6C (ii) and D (i)) and reduced NF-kB 
transcriptional activation (Fig. 6D(ii) P < 0.05).
5. Conclusion
In summary, our data suggest that a single dose of CeO2 nanoparticles is associated with 
improvements in animal survival, decreased hepatic damage, increased ceria deposition in 
the liver, and diminished evidence of systemic inflammation after a severe septic insult. In 
vitro experimentation using isolated Kupffer cells and cultured RAW264.7 macrophages 
demonstrated that CeO2 nanoparticle treatment decreased cytokine release (TNF-α, IL-1 β, 
IL-6, HMGB1), the induction of iNOS, NF-kB transcriptional activity following LPS 
challenge (Selvaraj et al. [16] Fig. 1), and MAPK (Selvaraj et al. [41] Fig. 1). Given that the 
large scale manufacture of these particles is possible using existing technology and their 
likely stability under a wide range of environmental conditions it is possible that these 
Selvaraj et al. Page 9













particles may have application for the treatment of sepsis in austere environments. 
Additional studies examining the potential efficacy of CeO2 nanoparticles for the treatment 
of sepsis may be warranted.
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Fig. 1. Characterization of CeO2 nanoparticles, animal survivability and physiological changes
A (i) Scanning electron microscopy (SEM) image of CeO2 nanoparticles, A (ii) 
Transmission electron microscopy (TEM) image of CeO2 nanoparticles, B (i) Dynamic light 
scattering (DLS) image of CeO2 nanoparticles, B (ii) X-ray diffraction image of CeO2 
nanoparticles, and C (i) X-ray photoelectron spectroscopy image of CeO2 nanoparticles. C 
(ii) Animal survivability of control (vehicle only, n = 6), CeO2 nanoparticle treated (0.5 
mg/kg, n = 6), sepsis (40 mg/kg of LPS, n = 16), and sepsis + CeO2 nanoparticle treatment 
(40 mg/kg of LPS + 0.5 mg/kg of CeO2 nanoparticles (n = 16)), D (i) Temperature, D (ii) 
Respiratory rate, and (E) Blood pressure. *P < 0.05 compared to control group, *#P < 0.05 
compared to LPS group.
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Fig. 2. Effect of CeO2 nanoparticles on LPS induced alteration of serum cytokines and 
chemokines
Cytokines changes: A (i) Tumor necrosis factor alpha (TNF-α), A (ii) interleukin 1 beta 
(IL-1β), B (i) Interleukin 1 alpha (IL-1α). Chemokines changes: B (ii) macrophage derived 
chemokines (MDC), C (i) macrophage inflammatory protein 1 beta (MIP-1β), C (ii) 
macrophage inflammatory protein-2 (MIP-2), D (i) macrophage inflammatory protein-3 beta 
(MIP-3β), D (ii) macrophage inflammatory protein-1 alpha (MIP-1α), E (i) monocyte 
chemotactic protein-1 (MCP-1), E (ii) monocyte chemotactic protein-3 (MCP-3), F (i) 
granulocytes chemotactic protein (GCP-2), and F (ii) growth regulated alpha protein (KC/
GROα). Serum samples were pooled from control (n = 6), CeO2 (n = 6), Sepsis (n = 6), 
Sepsis + CeO2 (n = 6) and analyzed in triplicate. Values are mean ± SEM of 3 independent 
experiments performed in triplicate. Statistical significance was determined by a one way 
ANOVA using Holm–Sidak test. *P < 0.05 compared to control group, *#P < 0.05 
compared to LPS group.
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Fig. 3. Protective effect of CeO2 nanoparticles on LPS-induced liver failure in vivo via MyD 
dependent MAP kinase pathway
A (i) nitric oxide production in serum, A (ii) presence of cerium in liver, A (iii) liver weight 
change. B histological change of liver (H & E, Scale bars = 100 μm), C (i) total bilirubin 
(TBIL), C (ii) alanine aminotransferase (ALT), C (iii) glutathione S transferae (GST-Mu) 
and D (i) glutathione S transferase (GST-α). Levels of total and phosphorylated proteins 
were determined by western blotting and normalized to GAPDH respectively, D (ii) MyD 
88, E (i) P-p38, and E (ii) P-ERK 44/42. Samples were pooled from control (n = 6), CeO2 (n 
= 6), Sepsis (n = 6), Sepsis + CeO2 (n = 6) and analyzed in triplicate. Values are mean ± 
SEM of 3 independent experiments performed in triplicate. Statistical significance was 
determined by a one way ANOVA using Holm–Sidak test. *P < 0.05 compared to control 
group, *#P < 0.05 compared to sepsis group.
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Fig. 4. Effect of CeO2 nanoparticles on inflammatory mediators, apoptosis and Kupffer cell 
changes induced by LPS
Levels of inflammatory mediator proteins were determined by western blotting and 
normalized to GAPDH respectively: A (i) iNOS, A (ii) HMGB1. B mitochondria dependent 
apoptosis was determined by TUNEL staining (Scale bar = 100 μm), A (iii) quantification of 
TUNEL positive nuclei, C (i) total and cleaved caspase-3, and C (ii) Bax/Bcl-2 ratio. 
Samples were pooled from control (n = 6), CeO2 (n = 6), Sepsis (n = 6), Sepsis + CeO2 (n = 
6) and analyzed in triplicate. Kupffer cell culture and changes: Cells were exposed to LPS in 
the presence and absence of CeO2 nanoparticles for 24 h (D) morphological changes (Scale 
bar = 200 μm), C (iii) TNF-α, and (E) ROS production (Scale bar = 200 μm). Kupffer cells 
were isolated from three different animals from each group at 3 different time points (n = 3). 
Values are mean ± SEM of 3 independent experiments performed in triplicate. Statistical 
significance was determined by a one way ANOVA using Holm–Sidak test. *P < 0.05 
compared to control group, *#P < 0.05 compared to sepsis group.
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Fig. 5. Effect of CeO2 nanoparticles on survival, ROS, Δψm, and cytokines production induced 
by LPS in RAW cells
Cells were exposed to LPS in the presence and absence of CeO2 nanoparticles for 24 h. A (i) 
protective effect of CeO2 nanoparticles against LPS insult, A (ii) CeO2 nanoparticles does 
not have any tendency to bind with LPS and neutralizing the functionality of LPS. B (i) 
amount of cerium oxide uptake by macrophage confirmed by ICP-MS analysis, B (ii) tumor 
necrosis factor alpha (TNF-α). C (i) interleukin-6 (IL-6), C (ii) interleukin-1 beta (IL-1β). D 
(i) high mobility box group protein-1 (HMGB1), D (ii) measurement of nitrite in the 
medium as determined by ELISA and E (i) and E (ii) expression of iNOS and COX-2 by 
western blot analysis. Values are mean ± SEM of 3 independent experiments. Statistical 
significance was determined by a one way ANOVA using Holm–Sidak test. *Significant 
difference from control (P < 0.05). *# Significant difference from LPS treatment (P < 0.05).
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Effect of CeO2 nanoparticles on NO production and the expression of iNOS and COX-2 and 
translocation of NF-kB/p65 in RAW 264.7 cells. Cells were exposed to LPS in the presence 
and absence of CeO2 nanoparticles for 24 h. A (i) reactive oxygen species production (ROS) 
was determined by 2, 7-dichlorodihydrofluorescein diacetate (DCFH-DA) (Scale bar = 50 
μm), A (ii) mitochondrial membrane potential (Δψm) was determined by JC-1 (Scale bar = 
50 μm). B (i) expression of IkB-α in whole cell lysate, B (ii) measurement of NF-kB in 
cytoplasmic and nuclear extracts C (i) by immunoblotting, C (ii) a representative image of 
EMSA binding of NF-kB to DNA and quantification of EMSA by densitometry D (i), and D 
(ii) NF-kB luciferase activity by Luciferase reporter assay. Values are mean ± SEM of 3 
independent experiments. *Significantly different from control (P < 0.05). *# Significantly 
different from LPS treatment (P < 0.05).
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